Literature DB >> 16211363

Angiogenesis in normal and neoplastic ovaries.

S Ramakrishnan1, I V Subramanian, Y Yokoyama, M Geller.   

Abstract

Ovarian physiology is intricately connected to hormonally regulated angiogenic response. Recent advances in the post genomic revolution have significantly impacted our understanding of ovarian function. In an angiogenesis perspective, the ovary offers a unique opportunity to unravel the molecular orchestration of blood vessel development and regression under normal conditions. A majority of ovarian cancers develop from the single layer of epithelium surrounding the ovaries. Angiogenesis is critical for the development of ovarian cancer and its peritoneal dissemination. The present review summarizes recent findings on the angiogenic response in neoplastic ovaries and discusses the prospects of using anti-angiogenic approaches to treat ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211363     DOI: 10.1007/s10456-005-9001-1

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  42 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib.

Authors:  Sarah E Bohndiek; Laura S Sasportas; Steven Machtaler; Jesse V Jokerst; Sharon Hori; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 10.057

3.  BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.

Authors:  Liisa Laatio; Päivi Myllynen; Raisa Serpi; Jaana Rysä; Mika Ilves; Elisa Lappi-Blanco; Heikki Ruskoaho; Kirsi Vähäkangas; Ulla Puistola
Journal:  Tumour Biol       Date:  2011-06-15

4.  Sprouty2 protein in prediction of post-treatment ascites in epithelial ovarian cancer treated with adjuvant carbotaxol chemotherapy.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; Ai-Qun Wei; Gregory Robertson; David L Morris
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  Contrast-enhanced sonography depicts spontaneous ovarian cancer at early stages in a preclinical animal model.

Authors:  Animesh Barua; Pincas Bitterman; Janice M Bahr; Sanjib Basu; Eyal Sheiner; Michael J Bradaric; Dale B Hales; Judith L Luborsky; Jacques S Abramowicz
Journal:  J Ultrasound Med       Date:  2011-03       Impact factor: 2.153

6.  Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.

Authors:  Yawu Jing; Huarui Lu; Kailang Wu; Indira V Subramanian; S Ramakrishnan
Journal:  Int J Cancer       Date:  2011-04-01       Impact factor: 7.396

Review 7.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis.

Authors:  Xue-Jiao Lv; Li-Jing Zhao; Yu-Qiu Hao; Zhen-Zhong Su; Jun-Yao Li; Yan-Wei Du; Jie Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Antiangiogenic drugs in ovarian cancer.

Authors:  G C Kumaran; G C Jayson; A R Clamp
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.